Head-to-head evidence
DT-101 vs Osavampator
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: AMPA receptor (positive allosteric modulator) · full Major Depressive Disorder pipeline
DT-101
Developed by Draig Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07610473 (registry estimate)
Osavampator
Developed by Takeda Pharmaceutical Company and partners
NCT05203341 · Phase 2 · completed
The trial randomized 183 participants to two osavampator doses or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical MADRS depression score at Day 28, but the comparison has not been reported, so the trial provides well-designed but currently incomplete evidence.
Next expected readout: July 2027 · NCT06786624 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DT-101's landscape · Osavampator's landscape